The global biosimilars market value could reach $20 billion by the end of 2015 according to GBI Research, and $55 billion by 2020, with growth primarily driven by a promising pipeline in development and government efforts to reduce healthcare spending.   The company’s latest CBR Pharma report states that biologics currently account for 17–20% of pharmaceuticals, with a value of approximately $200 billion, and these products may replace 70% of chemical drugs in the next two decades.   Sumith Ladd...